Advertisement
News
Advertisement

Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduc...

Mon, 04/04/2011 - 9:35am
Bio-Medicine.Org

SAN CLEMENTE, Calif., April 4, 2011 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI) today announced that three different clinical studies presented at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas showed that the MicroCLAVE neutral displacement needleless connector helps significantly reduce the risk of bacterial contamination and limit the incidence of hospital-acquired bloodstream infection when used in connection with an IHI bundle. ICU Medical initiated the full market release of the MicroCLAVE Clear at this year's SHEA meeting, highlighting the connector's clear housing that allows for visualization of the internal fluid path upon flushing and its ability to allow clinicians to effectively clear blood and blood residual with flush volumes as low as 2.0 mL.(1)

In a poster titled Three Years Experience of Central Line Associated Bloodstream Infections in the Intensive Care Units and Blood and Marrow Transplant Unit at an Academic Medical Center, researchers Concepcion N. Moore, RN, MBA, CIC , et al from the University Medical Center in Tucson, AZ showed that the rate of catheter-related bloodstream infections declined by 43% following the hospital-wide implementation of an IHI central line bundle that included the use of ICU Medical CLAVE® and MicroCLAVE connectors. Infection rates at the facility dropped from 5.09% in 2007 to 2.06% in 2010(1). The University Medical Center also uses both the MicroCLAVE Clear and Antimicrobial MicroCLAVE.(2)

Marcia Ryder, PhD, MS, RN, presented a poster titled Differences in Bacterial Transfer and Fluid Path Colonization through Needlefree Connector-Catheter Systems In-Vitro that evaluated differences in transfer of bacteria through the connector-catheter system and biofilm formation using an in-vitro model designed to simulate clinical use.

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading